0321日出づる処の名無し
2020/04/24(金) 06:02:40.96ID:+8km73rUDow pares some gains after report says Gilead's remesivir shows disappointing results
Published: April 23, 2020 at 1:00 p.m. ET
By Mark DeCambre
前日比で値上がりしていたダウ指数はGileadの新コロナウイルス薬のremesivirに
一部、期待はずれがあるとの報告で上げ幅を縮小
a article on a closely followed therapeutic intended to help treat COVID-19 was
reported to have shown disappointing results in a trial, according to an article
by the Financial Times. A clinical trial on the Gilead GILD, -4.72% drug remdesivir
had been viewed by the World Health Organization and accidentally published, the
FT reported. The paper said that researchers studied 237 patients, giving the drug
to 158 and comparing their progress with the remaining 79. The story indicated that
the drug showed significant side effects in some, with 18 patients taken off it.
The Dow Jones Industrial Average DJIA, 0.94% was bouncing around in afternoon action,
well of its highs, and was trading up 123 points, or 0.5%, at 23,589, the S&P 500
index SPX, 0.78% was up 0.5% at 2,812, while the Nasdaq Composite Index COMP, 0.92%
was up 0.6% at 8,551. Meanwhile, shares of Gilead were down nearly 4% Thursday.
A report last week from Stat News indicated that remdesivir was seeing some success
but the research linked to that report was not based on a clinical study.
